Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben-Horin

Showing results (1-10 of 415) with videos related to

Pageof 42
Sort By:
Psychopharmacology|January 1, 1984
The effects of proglumide on morphine induced motility changesN Ben-Horin, E Ben-Horin, H Frenk
Gastroenterology & Hepatology|April 29, 2017
Reversal of Immunogenicity in Inflammatory Bowel DiseaseShomron Ben-Horin
Alimentary Pharmacology & Therapeutics|February 16, 2018
Editorial: restoring therapeutic infliximab drug levels in patients with loss of response-pharmacokinetics and anti-drug antibodies as useful guidance toolsS Ben-Horin
Gastroenterology|April 30, 2015
Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?Shomron Ben-Horin
Gut|May 27, 2011
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitisShomron Ben-Horin
Digestive Diseases (Basel, Switzerland)|June 28, 2014
Loss of response to anti-tumor necrosis factors: what is the next step?Shomron Ben-Horin
Physical Review Letters|January 9, 1989
Multistate isomerization of size-selected clustersEven, Ben-Horin, Jortner
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Expert Opinion on Biological Therapy|August 13, 2019
CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel diseaseAhmad Albshesh, Shomron Ben-Horin
United European Gastroenterology Journal|July 19, 2019
Biologics' switching: new insights toward establishing practice normsHussein Mahagna, Shomron Ben-Horin
Pageof 42

Showing results (1-10 of 415) with videos related to

Sort By:
Pageof 42
Psychopharmacology|January 1, 1984
The effects of proglumide on morphine induced motility changesN Ben-Horin, E Ben-Horin, H Frenk
Gastroenterology & Hepatology|April 29, 2017
Reversal of Immunogenicity in Inflammatory Bowel DiseaseShomron Ben-Horin
Alimentary Pharmacology & Therapeutics|February 16, 2018
Editorial: restoring therapeutic infliximab drug levels in patients with loss of response-pharmacokinetics and anti-drug antibodies as useful guidance toolsS Ben-Horin
Gastroenterology|April 30, 2015
Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?Shomron Ben-Horin
Gut|May 27, 2011
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitisShomron Ben-Horin
Digestive Diseases (Basel, Switzerland)|June 28, 2014
Loss of response to anti-tumor necrosis factors: what is the next step?Shomron Ben-Horin
Physical Review Letters|January 9, 1989
Multistate isomerization of size-selected clustersEven, Ben-Horin, Jortner
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Expert Opinion on Biological Therapy|August 13, 2019
CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel diseaseAhmad Albshesh, Shomron Ben-Horin
United European Gastroenterology Journal|July 19, 2019
Biologics' switching: new insights toward establishing practice normsHussein Mahagna, Shomron Ben-Horin
Pageof 42